News headlines about Fate Therapeutics (NASDAQ:FATE) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.1409048476544 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
- Fate Therapeutics, Inc. (NASDAQ:FATE) – Market Cap to Track – Nasdaq Journal (nasdaqjournal.com)
- Fate Therapeutics, Inc. (FATE) : Are you searching Analysts Rated Stock – Wall Street Morning (wallstreetmorning.com)
- Wired News – CTI BioPharma’s Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology (finance.yahoo.com)
- Short Interest in Fate Therapeutics Inc (FATE) Expands By 28.7% (americanbankingnews.com)
- Leerink Swann Comments on Fate Therapeutics Inc’s FY2018 Earnings (FATE) (americanbankingnews.com)
A number of equities research analysts have recently weighed in on FATE shares. ValuEngine cut Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Raymond James Financial reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Fate Therapeutics in a report on Wednesday, December 13th. Piper Jaffray Companies started coverage on Fate Therapeutics in a report on Monday, December 18th. They set an “overweight” rating and a $10.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 price target on shares of Fate Therapeutics in a report on Monday, December 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Fate Therapeutics has an average rating of “Buy” and a consensus target price of $13.00.
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. The firm’s revenue was up .0% compared to the same quarter last year. sell-side analysts forecast that Fate Therapeutics will post -0.91 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by BBNS and is the property of of BBNS. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://baseballnewssource.com/2018/03/14/fate-therapeutics-fate-earns-daily-news-impact-score-of-0-16/2027249.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.